NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









QurAlis

QurAlis

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.quralis.com/

Last Round

Series B

Extension

Aug 21, 2025

Total Funding Raised

$161.5M

Company Overview

QurAlis is a biotechnology company that develops precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases using genetically validated targets.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

precision medicineALS drugneurodegenerative diseasedrug discoverybiotech startupamyotrophic lateral sclerosisfrontotemporal dementiaclinical stage biotechdrug screening platformASOantisense oligonucleotidebiopharma partnershipphenotypic screeningAI drug discoveryin silico drug design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

QurAlis Comps

Public and private peers based on sector, stage, and business model.

QurAlis comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

QurAlis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionAug 21, 2025
Series BMar 9, 2023
Series AMay 13, 2020
SeedNov 19, 2018
SeedApr 5, 2018

Key People

Founding team and executive leadership

Hagen Cramer

Chief Technology Officer

Executive Team

Jason Parker Brown

CFO & COO

Executive Team

QurAlis Investors

Notable investors and investment history

QurAlis investors
InvestorRounds
The ALS AssociationGrant
EQT Life SciencesSeries B
Dolby Family VenturesSeries A, Series B
MP Healthcare Venture ManagementSeries A, Seed, Series B
Mitsui Global InvestmentSeries A, Series B
AcksSeed
Droia VenturesSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 2, 2025

    Presenting Phase 1 data for QRL-101, a selective Kv7.2/7.3 ion channel opener.

  • Dec 2, 2025

    Presenting Phase 1 trial data at the American Epilepsy Society 2025 Annual Meeting.

QurAlis Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

QurAlis Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about QurAlis's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range87
Year Founded2016
Last FundingAug 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.